Show simple item record

dc.contributor.advisorCharles L. Cooney and Roy Welsch.en_US
dc.contributor.authorAssia, Shaien_US
dc.contributor.otherLeaders for Global Operations Program.en_US
dc.date.accessioned2014-10-08T15:27:45Z
dc.date.available2014-10-08T15:27:45Z
dc.date.copyright2014en_US
dc.date.issued2014en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/90765
dc.descriptionThesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2014. In conjunction with the Leaders for Global Operations Program at MIT.en_US
dc.descriptionThesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2014. In conjunction with the Leaders for Global Operations Program at MIT.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (pages 87-88).en_US
dc.description.abstractMonoclonal Antibodies (mAb's) are the fastest growing segment in the biopharmaceutical industry. They are used today as therapeutics and diagnostics for several medical applications, including various types of cancer, rheumatoid arthritis, psoriasis, severe asthma macular degeneration, multiple sclerosis and more. In recent years, industry trends and market pressure have driven pharmaceutical companies to focus efforts on increasing operational efficiency in order to reduce the financial burden associated with drug manufacturing. Consequentially, Novartis Pharma Technical Operations' is currently engaging in efforts to obtain Class "A" Manufacturing Resource Planning (MRP II). This project was chosen to analyze and address the current Integrated Business Planning (IBP) technically and financially by analyzing critical processes, their bottlenecks, and prioritizing improvement opportunities. We focus on tactical planning at the Multiproduct Process Unit at BioPharm Ops. This paper describe the development of a Tactical Planning optimization tool, which implements SuperPro Designerc and ScheduleProC (Intelligen Inc., NJ, USA) for campaign scheduling of active pharmaceutical ingredient production based on mammalian monoclonal antibodies (mAb's). Results have shown great potential benefits for Novartis, including but not limited to: Creating and modifying campaign schedules in hours (not days); increased operational efficiency; Max Run Rate Optimization, cycle time reduction and significant production cost savings; analytic tool to support long-term strategic decisions with the flexibility to address real-time adversity and automated conflict resolving.en_US
dc.description.statementofresponsibilityby Shai Assia.en_US
dc.format.extent95 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectMechanical Engineering.en_US
dc.subjectLeaders for Global Operations Program.en_US
dc.titleTactical planning optimization for campaign scheduling of active pharmaceutical ingredient production based on monoclonal antibodiesen_US
dc.typeThesisen_US
dc.description.degreeM.B.A.en_US
dc.description.degreeS.M.en_US
dc.contributor.departmentSloan School of Management.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Mechanical Engineering.en_US
dc.contributor.departmentLeaders for Global Operations Program.en_US
dc.identifier.oclc891383784en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record